Kumkuma (Saffron) in Ayurveda: Properties & Everyday Use

What it is

Kumkuma is saffron: the dried red stigmas of Crocus sativus L., a small purple-flowered crocus cultivated primarily in Iran, Greece, and India ("derived from the red stigmas of the Crocus flower," Tufail et al., Food Sci Nutr 2025). It is one of the costliest spices in the world (same review). Its characteristic compounds include crocin (the carotenoid behind its color), safranal (behind its aroma), and crocetin: the constituents most discussed in pharmacological and toxicological reviews (same functional review; toxicology review, PMC). Saffron's health-promoting properties are also described in ancient Chinese, Unani, and Ayurvedic prescriptions (same functional review).

Classical properties

• Taste (rasa): bitter (Tikta), sweet (Madhura)
• Qualities (guna): light (Laghu)
• Potency (virya): warming (Ushna)
• After digestion (vipaka): sweet (Madhura)
• Doshas: traditionally said to settle Vata and Pitta; may increase Kapha

Traditional use

Traditional-medicine texts have long listed saffron for low mood: as the background of a 2004 clinical trial put it, "*Crocus sativus* L. is used to treat depression. Many medicinal plants textbooks refer to this indication whereas there is no evidence-based document" (Akhondzadeh et al., BMC Complement Altern Med). In Ayurveda, kumkuma is a prized ingredient of classical preparations such as Kumkumadi Taila, and in Persian medicine saffron has centuries of use as a mood and vitality remedy. These are traditional claims, not clinical proof: the trial evidence is assessed separately below.

What research has looked at

Depression

The strongest human evidence concerns mild-to-moderate depression. A 2013 meta-analysis pooled five randomized controlled trials (two placebo-controlled, three antidepressant-controlled) and found a large effect for saffron versus placebo (mean effect size 1.62, P<0.001) Three of the trials compared saffron with antidepressant drugs; these small comparisons are preliminary and do not show that saffron can stand in for medicine. Never use it in place of, or alongside, prescribed medicine without your doctor. All five trials ran for 6–8 weeks, and the included trials were rated high quality (mean Jadad score 5). But the trials were small, short, and concentrated in Iran, and the authors called for larger, longer trials by research teams outside Iran before firm conclusions (Hausenblas et al., J Integr Med). Disclosure: the meta-analysis authors Drs. Anton and Hausenblas served as scientific advisors and consultants for ReBody LLC, an affiliate of Reserve Life Organics/Reserveage Organics, a marketer of a saffron-containing product. The paper states neither received personal financial gain from product sales.

A 2020 meta-analysis of 21 randomized trials found saffron significantly reduced Beck Depression Inventory scores (weighted mean difference −4.86; 95% CI −6.58 to −3.14), Beck Anxiety Inventory scores (−5.29; −8.27 to −2.31), and Pittsburgh Sleep Quality Index scores (−2.22; −2.73 to −1.72): but found no significant effect on Hamilton depression/anxiety rating scales or on C-reactive protein (Mazidi et al., Complement Ther Med). The split result (benefit on self-report scales, none on clinician-rated scales) is worth noting.

Individual trials behind these numbers include a 6-week pilot double-blind RCT (n=30) in mild-to-moderate depression that compared saffron with the antidepressant imipramine. The authors called it a pilot and said a large-scale placebo-controlled trial was warranted (Akhondzadeh et al., 2004). A later 6-week trial in 40 post–coronary-intervention patients compared saffron with fluoxetine, but the sample was small and the period short (Akhondzadeh et al., J Affect Disord).

PMS and dysmenorrhea

A 2025 systematic review and meta-analysis of randomized trials of saffron for premenstrual syndrome and dysmenorrhea found a significant benefit for PMS symptoms (standardized mean difference −0.64; 95% CI −0.84 to −0.44) and for dysmenorrhea (−0.51; −1.01 to −0.01) (Mohammadi & Karimi, Korean J Fam Med). A second 2025 meta-analysis pooled three RCTs and likewise found a significant effect on PMS (mean difference 0.63, p=0.03), while noting methodological flaws in the included studies and calling for further trials (Maleki et al., Rev Clin Med).

What the evidence does not support (yet)

The trials are small (mostly 30–80 participants), short (typically 6–8 weeks), and concentrated in Iran. Saffron has not been shown effective for severe depression, and no trial supports using it as a replacement for prescribed antidepressants. Saffron has also been explored for cognitive disorders, but the human data there are preliminary (functional review).

Safety notes

Saffron at the amounts used in trials appears well tolerated, and a toxicology review concluded that therapeutic doses in clinical trials did not produce significant toxicity: while stressing that human safety evidence is limited and inconsistent (PMC toxicology review). The commonly reported adverse effects in the depression trials were headache, nausea, anxiety, and decreased appetite (Hausenblas et al.). The cautions matter more than the reassurance:

• During pregnancy, high amounts are best avoided. The toxicology review advises pregnant women to avoid high doses because pregnancy safety data are insufficient. Higher abortion rates have been reported among workers exposed to high saffron levels, but that occupational finding cannot be converted into precise medicinal dose thresholds (PMC toxicology review). Animal high-dose findings vary.
• Allergic reactions are possible, as with any plant product.
• Medication caution: saffron has demonstrated effects on depressive symptoms in trials, so discuss it with a clinician if you take prescription medicines: including mood medicines.
• One one-week study found no coagulation effects at the amounts tested, but that is a single small finding, not a safety guarantee (PMC toxicology review).

FAQs

Does saffron help with depression?

The trial evidence is unusually favorable for an herb: a 2013 meta-analysis of 5 RCTs found a large symptom reduction versus placebo in mild-to-moderate depression (Hausenblas et al.), and a 2020 meta-analysis of 21 trials found significant improvements on depression, anxiety, and sleep self-report scales (Mazidi et al.). Trials are small, short, and mostly from Iran.

Is saffron as effective as antidepressant drugs?

No trial shows that. A few small, short, Iran-concentrated pilot trials compared saffron with antidepressants, and they are too preliminary to show that saffron matches a prescribed medicine (Hausenblas et al.; Akhondzadeh et al., 2004). Saffron is not a depression treatment. Never use it in place of, or alongside, prescribed medicine without your doctor.

Does saffron help with PMS?

A 2025 meta-analysis of randomized trials found saffron significantly reduced PMS symptoms (SMD −0.64) and dysmenorrhea (SMD −0.51) (Mohammadi & Karimi). A second 2025 meta-analysis agreed but flagged methodological flaws and called for more trials (Maleki et al.).

What dose of saffron was used in studies?

Swastik does not suggest amounts. The right amount depends on the person, the preparation and the product, so check with a qualified Ayurvedic practitioner or your doctor before taking any herb.

Is saffron safe during pregnancy?

In pregnancy, amounts beyond food are not advised. A toxicology review advises pregnant women to avoid high doses because pregnancy safety data are insufficient. Higher abortion rates were reported among workers exposed to high saffron levels, but that finding cannot set a medicinal dose threshold (PMC toxicology review).

Can saffron be toxic?

At culinary and trial doses, saffron shows little toxicity, but toxic effects are dose-dependent and human safety evidence is limited and inconsistent; animal high-dose findings vary (PMC toxicology review).

Sources

• Hausenblas HA et al. "Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials." J Integr Med. 2013;11(6):377–383 — PubMed · PMID 24299602
• Mazidi M et al. "The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials." Complement Ther Med. 2020;48:102250 — PubMed · PMID 31987241
• Mohammadi MM, Karimi Z. "Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis." Korean J Fam Med. 2025 — PubMed · PMID 41151539
• Maleki N et al. "Efficacy of saffron (Crocus sativus) in the Treatment of Premenstrual Syndrome: A Systematic Review and Meta-analysis." Rev Clin Med. 2025 — rcm.mums.ac.ir
• Akhondzadeh S et al. "Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial." BMC Complement Altern Med. 2004;4:12 — PubMed · PMID 15341662
• Akhondzadeh S et al. "A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients." J Affect Disord. 2014;155:216–222 — PubMed · PMID 24289892
• "Toxicology effects of saffron and its constituents: a review." Avicenna J Phytomed. 2015 — PMC · PMC5339650
• Tufail T et al. "Functional, Nutraceutical and Health Endorsing Perspectives of Saffron." Food Sci Nutr. 2025;13:e70721 — PMC · PMC12326435

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.